Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.26 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tarenflurbil, rg-4733, nirogacestat +4 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 79 | 0.91 |
| pathways Reactome | 13 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1636
Sealed predictions
- APH1A in dopamine neurons, braak-0.75 (p 0.020) → -0.29 (p 0.445)receipt 1642
Swarm cases
receipt 1642: APH1A in dopamine neurons, braak
- power
- full sample -0.52 (p 0.028, n 18), 95% CI -0.79 to -0.07. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.48 (p 0.043, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range -0.60 to -0.45, sign flips 0; without severely affected donors -0.52 (p 0.028, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APH1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts